NCT07076680 2025-11-28A Real-World Study in Patients With HR+/HER2- Advanced Breast CancerSciClone PharmaceuticalsWithdrawn
NCT04509596 2025-04-01DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast CancerDizal PharmaceuticalsPhase 1 Completed23 enrolled